276 related articles for article (PubMed ID: 35510600)
1. Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA.
Kumari R; Kumar V; Dhankhar P; Dalal V
J Biomol Struct Dyn; 2023 Jul; 41(10):4650-4666. PubMed ID: 35510600
[TBL] [Abstract][Full Text] [Related]
2. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
Rahul S; Sarkar A
J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
[TBL] [Abstract][Full Text] [Related]
3. Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids.
Thangavel N; Albratty M
J King Saud Univ Sci; 2023 Jan; 35(1):102402. PubMed ID: 36338939
[TBL] [Abstract][Full Text] [Related]
4. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches.
Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151
[TBL] [Abstract][Full Text] [Related]
5. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
[TBL] [Abstract][Full Text] [Related]
6. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
Amin SA; Ghosh K; Gayen S; Jha T
J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
[TBL] [Abstract][Full Text] [Related]
7. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
8. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
10. Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study.
Ribaudo G; Yun X; Ongaro A; Oselladore E; Ng JPL; Haynes RK; Law BYK; Memo M; Wong VKW; Coghi P; Gianoncelli A
Chem Biol Drug Des; 2023 Apr; 101(4):809-818. PubMed ID: 36453012
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
12. Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease.
Zou Z; Shan H; Sun D; Xia L; Shi Y; Wan J; Zhou A; Wu Y; Xu H; Lei H; Xu Z; Wu Y
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1133-1139. PubMed ID: 35866602
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease.
Liu W; Wang J; Wang S; Yue K; Hu Y; Liu X; Wang L; Wan S; Xu X
Bioorg Chem; 2023 Nov; 140():106830. PubMed ID: 37683544
[TBL] [Abstract][Full Text] [Related]
14. Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies.
Patil VR; Dhote AM; Patil R; Amnerkar ND; Lokwani DK; Ugale VG; Charbe NB; Firke SD; Chaudhari P; Shah SK; Mehta CH; Nayak UY; Khadse SC
J Biomol Struct Dyn; 2023; 41(22):13168-13179. PubMed ID: 36757134
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
16. A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2.
Singh E; Jha RK; Khan RJ; Kumar A; Jain M; Muthukumaran J; Singh AK
Comput Biol Chem; 2022 Aug; 99():107721. PubMed ID: 35835027
[TBL] [Abstract][Full Text] [Related]
17.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
18. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
Kiba Y; Tanikawa T; Kitamura M
Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
[TBL] [Abstract][Full Text] [Related]
19. Molecular modelling on SARS-CoV-2 papain-like protease: an integrated study with homology modelling, molecular docking, and molecular dynamics simulations.
Arwansyah A; Arif AR; Ramli I; Kurniawan I; Sukarti S; Nur Alam M; Illing I; Farid Lewa A; Manguntungi B
SAR QSAR Environ Res; 2021 Sep; 32(9):699-718. PubMed ID: 34392751
[TBL] [Abstract][Full Text] [Related]
20. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2.
Islam R; Parves MR; Paul AS; Uddin N; Rahman MS; Mamun AA; Hossain MN; Ali MA; Halim MA
J Biomol Struct Dyn; 2021 Jun; 39(9):3213-3224. PubMed ID: 32340562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
